Our recently completed single-arm phase II study of panitumumab (PmAb), a human IgG2 anti-EGFR monoclonal antibody, combined with chemotherapy (NCT01036087) showed the highest ever observed pathological complete tumor response (pCR) rate to preoperative treatment in patients with HER2-negative IBC (29%, compared to a historical pCR rate of 15%); of note, a pCR rate of 47% was observed in the triple-negative subset [16]. This evidence concerns the gene EGFR and inflammatory breast carcinoma.